Skip to main content
logo
Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
3.580
0.00 (0.00%)
At close: Jun 5, 2026, 4:00 PM EDT
3.490
-0.090 (-2.51%)
After-hours: Jun 5, 2026, 6:18 PM EDT

Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.

Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain.

The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery.

The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc.
Nutriband logo
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees13
CEOGareth Sheridan

Contact Details

Address:
121 South Orange Avenue, Suite 1500
Orlando, Florida 32801
United States
Phone407 377 6695
Websitenutriband.com

Stock Details

Ticker SymbolNTRB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearFebruary - January
Reporting CurrencyUSD
CIK Code1676047
CUSIP Number67092M208
ISIN NumberUS67092M2089
Employer ID81-1118176
SIC Code3842

Key Executives

NamePosition
Gareth SheridanFounder, Chief Executive Officer and Director
Serguei MelnikFounder, President, Company Secretary and Executive Chairman
Gerald GoodmanChief Financial Officer and Chief Accounting Officer
Dr. Alan Smith Ph.D.Chief Operating Officer and President of 4P Therapeutics
Dr. Jeffrey Patrick Pharm.D.Chief Scientific Officer
Michael MyerPresident of Pocono Pharmaceutical
Tyler OverkHead of Active Intelligence

Latest SEC Filings

DateTypeTitle
May 18, 202610-K/A[Amend] Annual report
Apr 29, 202610-KAnnual Report
Apr 7, 20268-KCurrent Report
Feb 13, 20268-KCurrent Report
Feb 13, 2026424B3Prospectus
Feb 3, 20268-KCurrent Report
Dec 30, 20258-KCurrent Report
Dec 19, 2025DEF 14AOther definitive proxy statements
Dec 11, 202510-QQuarterly Report
Oct 28, 20258-KCurrent Report
View All SEC Filings